Stay updated on ABT-450/r/ABT-267 and ABT-333 with RBV in Asian Adults Clinical Trial

Sign up to get notified when there's something new on the ABT-450/r/ABT-267 and ABT-333 with RBV in Asian Adults Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABT-450/r/ABT-267 and ABT-333 with RBV in Asian Adults Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase 3 clinical trial evaluating the efficacy and safety of ABT-450/r/ ABT-267 and ABT-333 coadministered with ribavirin in Asian adults with chronic hepatitis C virus (HCV) infection and compensated cirrhosis.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that they must be of Chinese, South Korean, or Taiwanese descent with chronic HCV-infection and compensated cirrhosis, among other health conditions.
    Difference
    30%
    Check dated 2024-05-22T21:21:21.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:26:18.000Z thumbnail image

Stay in the know with updates to ABT-450/r/ABT-267 and ABT-333 with RBV in Asian Adults Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABT-450/r/ABT-267 and ABT-333 with RBV in Asian Adults Clinical Trial page.